Tolerance is the key to understanding antimalarial drug resistance

Ian M Hastings1, William M Watkins

  • 1Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. hastings@liverpool.ac.uk

Trends in Parasitology
|January 13, 2006
PubMed

Insights

Antimalarial drug resistance is more complex than a simple sensitive or resistant state. A crucial intermediate stage of drug tolerance allows parasites to spread, impacting malaria evolution.

Area of Science:

  • Malariology
  • Parasitology
  • Evolutionary Biology

Background:

  • Antimalarial drug resistance is typically viewed as a binary process (sensitive vs. resistant).
  • This overlooks the critical intermediate stage of drug tolerance in malaria parasites.
  • Drug tolerance presents unique challenges for malaria control strategies.

Purpose of the Study:

  • To highlight the significance of drug tolerance in the evolution of antimalarial drug resistance.
  • To explain the mechanism by which drug-tolerant malaria parasites can persist and spread.
  • To underscore the implications of this intermediate stage for malaria treatment and eradication.

Main Methods:

  • Conceptual analysis of parasite resistance evolution.
  • Review of pharmacokinetic and pharmacodynamic principles of antimalarial drugs.
  • Modeling parasite population dynamics under drug pressure.

Main Results:

  • Drug-tolerant malaria parasites survive sub-curative drug concentrations present post-treatment.
  • These tolerant parasites can infect new hosts, facilitating their propagation.
  • The persistence of residual drug levels enables the spread of tolerant strains.

Conclusions:

  • Drug tolerance represents a crucial, often underestimated, phase in the development of full antimalarial drug resistance.
  • Understanding and addressing drug tolerance is vital for preventing the emergence and spread of resistant malaria.
  • This intermediate stage has significant implications for global malaria eradication efforts.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...